In 1997, the presence of fetal DNA in maternal plasma and serum was reported by a group of professors from CUHK. It is now known that those cell-free DNA in the maternal circulation during pregnancy comes from the fetoplacental unit, most of which is shed from the placenta. By a single blood draw, is able to screen for fetal chromosomal aneuploidies such as Down Syndrome (T21), Edwards Syndrome (T18) and Patau Syndrome (T13) etc.
utilizes Next Generation Sequencing technique and bioinformatics analysis on both maternal DNA and cell free placental DNA found in maternal blood. Compared to traditional screening methods based on nuchal translucency or maternal age, is more sensitive,reliable, accurate and informative.
During pregnancy, the fetus releases some of the cell-free DNA into the blood circulation of its mother.
DNA from the fetus is obtained by drawing 10mL of maternal blood.
Safe T21 express analyses the circulating cell-free DNA molecules by NGS technology followed by bioinformatics analysis.
The report containing the genetic information of the fetus will be available in 5 working days.
offers screening for twins, triplets, and in vitro fertilization (IVF) cases